A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma
Clinical trial NCT03957590 · COMPLETED
Trial details
- NCT number
- NCT03957590
- Sponsor
- BeiGene
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2019-06-11
- Primary completion
- 2025-01-08
- Enrollment
- 370
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.